Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
Purpose Tumor angiogenesis controlled predominantly by vascular endothelial growth factor and its receptor (VEGF-VEGFR) interaction plays a key role in the growth and propagation of cancer cells. However, the newly formed network of blood vessels is disorganized and leaky. Pre-treatment with anti-angiogenic agents can “normalize” the tumor vasculature allowing effective intra-tumoral delivery of standard chemotherapy. Immunohistochemistry (IHC) analysis was applied to investigate and compare the vascular normalization and anti-angiogenic effects of two commonly used anti-angiogenic agents, Sunitinib and Bevacizumab, administered prior to chemotherapy in HER2-negative breast cancer patients. Methods This prospective clinical trial enrolled 38 patients into a sunitinib cohort and 24 into a bevacizumab cohort. All received 4 cycles of doxorubicin/cyclophosphamide chemotherapy and pre-treatment with either sunitinib or bevacizumab. Tumor biopsies were obtained at baseline, after cycle 1 (C1) and cycle 4 (C4) of chemotherapy. IHC was performed to assess the tumor vascular normalization index (VNI), lymphatic vessel density (LVD), Ki67 proliferation index and expression of tumor VEGFR2. Results In comparison to Bevacizumab, Sunitinib led to a significant increase in VNI post-C1 and C4 (p < 0.001 and 0.001) along with decrease in LVD post-C1 (p = 0.017). Both drugs when combined with chemotherapy resulted in significant decline in tumor proliferation after C1 and C4 (baseline vs post-C4 Ki67 index p = 0.006 for Sunitinib vs p = 0.021 for Bevacizumab). Bevacizumab resulted in a significant decrease in VEGFR2 expression post-C1 (p = 0.004). Conclusion Sunitinib, in comparison to Bevacizumab showed a greater effect on tumor vessel modulation and lymphangiogenesis suggesting that its administration prior to chemotherapy might result in improved drug delivery. Trial registry ClinicalTrials.gov: NCT02790580 (first posted June 6, 2016)..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:192 |
|---|---|
| Enthalten in: |
Breast cancer research and treatment - 192(2021), 1 vom: 20. Dez., Seite 131-142 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yadav, Kritika [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Anti-angiogenic |
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1007/s10549-021-06470-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078032042 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078032042 | ||
| 003 | DE-627 | ||
| 005 | 20230518001304.0 | ||
| 007 | tu | ||
| 008 | 221220s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10549-021-06470-7 |2 doi | |
| 035 | |a (DE-627)OLC2078032042 | ||
| 035 | |a (DE-He213)s10549-021-06470-7-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Yadav, Kritika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Purpose Tumor angiogenesis controlled predominantly by vascular endothelial growth factor and its receptor (VEGF-VEGFR) interaction plays a key role in the growth and propagation of cancer cells. However, the newly formed network of blood vessels is disorganized and leaky. Pre-treatment with anti-angiogenic agents can “normalize” the tumor vasculature allowing effective intra-tumoral delivery of standard chemotherapy. Immunohistochemistry (IHC) analysis was applied to investigate and compare the vascular normalization and anti-angiogenic effects of two commonly used anti-angiogenic agents, Sunitinib and Bevacizumab, administered prior to chemotherapy in HER2-negative breast cancer patients. Methods This prospective clinical trial enrolled 38 patients into a sunitinib cohort and 24 into a bevacizumab cohort. All received 4 cycles of doxorubicin/cyclophosphamide chemotherapy and pre-treatment with either sunitinib or bevacizumab. Tumor biopsies were obtained at baseline, after cycle 1 (C1) and cycle 4 (C4) of chemotherapy. IHC was performed to assess the tumor vascular normalization index (VNI), lymphatic vessel density (LVD), Ki67 proliferation index and expression of tumor VEGFR2. Results In comparison to Bevacizumab, Sunitinib led to a significant increase in VNI post-C1 and C4 (p < 0.001 and 0.001) along with decrease in LVD post-C1 (p = 0.017). Both drugs when combined with chemotherapy resulted in significant decline in tumor proliferation after C1 and C4 (baseline vs post-C4 Ki67 index p = 0.006 for Sunitinib vs p = 0.021 for Bevacizumab). Bevacizumab resulted in a significant decrease in VEGFR2 expression post-C1 (p = 0.004). Conclusion Sunitinib, in comparison to Bevacizumab showed a greater effect on tumor vessel modulation and lymphangiogenesis suggesting that its administration prior to chemotherapy might result in improved drug delivery. Trial registry ClinicalTrials.gov: NCT02790580 (first posted June 6, 2016). | ||
| 650 | 4 | |a Anti-angiogenic | |
| 650 | 4 | |a Bevacizumab | |
| 650 | 4 | |a HER2-negative breast cancer | |
| 650 | 4 | |a Sunitinib | |
| 650 | 4 | |a Vascular normalization | |
| 700 | 1 | |a Lim, Joline |4 aut | |
| 700 | 1 | |a Choo, Joan |4 aut | |
| 700 | 1 | |a Ow, Samuel Guan Wei |4 aut | |
| 700 | 1 | |a Wong, Andrea |4 aut | |
| 700 | 1 | |a Lee, Matilda |4 aut | |
| 700 | 1 | |a Chan, Ching Wan |4 aut | |
| 700 | 1 | |a Hartman, Mikael |4 aut | |
| 700 | 1 | |a Lim, Siew Eng |4 aut | |
| 700 | 1 | |a Ngoi, Natalie |4 aut | |
| 700 | 1 | |a Tang, Siau Wei |4 aut | |
| 700 | 1 | |a Ang, Yvonne |4 aut | |
| 700 | 1 | |a Chan, Gloria |4 aut | |
| 700 | 1 | |a Chong, Wan Qin |4 aut | |
| 700 | 1 | |a Tan, Hon Lyn |4 aut | |
| 700 | 1 | |a Tan, Sing Huang |4 aut | |
| 700 | 1 | |a Goh, Boon Cher |4 aut | |
| 700 | 1 | |a Lee, Soo Chin |0 (orcid)0000-0002-5835-6419 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer research and treatment |d Springer US, 1981 |g 192(2021), 1 vom: 20. Dez., Seite 131-142 |w (DE-627)167913557 |w (DE-600)604563-7 |w (DE-576)01590217X |x 0167-6806 |7 nnns |
| 773 | 1 | 8 | |g volume:192 |g year:2021 |g number:1 |g day:20 |g month:12 |g pages:131-142 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10549-021-06470-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 192 |j 2021 |e 1 |b 20 |c 12 |h 131-142 | ||